CIK 0000316253
ENZ ENZO BIOCHEM INC
Insider trading from SEC Form 4. Last filing Aug 20, 2025.
ENZO BIOCHEM INC (ENZ) has 8 SEC Form 4 filings on file from 5 insiders, the latest filed on Aug 20, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at ENZO BIOCHEM INC, scored.
Transactions
Every row filed, 24 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 20, 2025 | Jonathan Couchman director | DDisposition to issuer Common Stock | -142,897 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Bradley Louis Radoff director | DDisposition to issuer Common Stock | -4,533,779 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Steven J Pully director | DDisposition to issuer Common Stock | -239,992 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Kara Cannon Chief Executive Officer | DDisposition to issuer Common Stock | -359,737 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Patricia Eckert Chief Financial Officer | DDisposition to issuer Common Stockindirect: 401k | -28,328 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Jonathan Couchman director | DDisposition to issuer Common Stockindirect: By Xstelos Holdings, Inc. | -130,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Bradley Louis Radoff director | DDisposition to issuer Common Stockindirect: By The Radoff Family Foundation | -430,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Patricia Eckert Chief Financial Officer | DDisposition to issuer Stock Option (to acquire shares of Common Stock)derivative | -100,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Kara Cannon Chief Executive Officer | DDisposition to issuer Common Stockindirect: 401k | -45,065 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Kara Cannon Chief Executive Officer | DDisposition to issuer Stock Option (to acquire shares of Common Stock)derivative | -200,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Patricia Eckert Chief Financial Officer | DDisposition to issuer Stock Option (to acquire shares of Common Stock)derivative | -75,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Jonathan Couchman director | DDisposition to issuer Common Stockindirect: By Myrexis, Inc. | -40,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Kara Cannon Chief Executive Officer | DDisposition to issuer Stock Option (to acquire shares of Common Stock)derivative | -200,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Patricia Eckert Chief Financial Officer | DDisposition to issuer Stock Option (to acquire shares of Common Stock)derivative | -25,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Jonathan Couchman director | DDisposition to issuer Common Stockindirect: By Couchman Family Fund | -15,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Kara Cannon Chief Executive Officer | DDisposition to issuer Stock Option (to acquire shares of Common Stock)derivative | -87,500 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Patricia Eckert Chief Financial Officer | DDisposition to issuer Stock Option (to acquire shares of Common Stock)derivative | -50,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Jonathan Couchman director | DDisposition to issuer Common Stockindirect: In retirement accounts | -277,237 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Kara Cannon Chief Executive Officer | DDisposition to issuer Stock Option (to acquire shares of Common Stock)derivative | -87,500 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Patricia Eckert Chief Financial Officer | DDisposition to issuer Stock Option (to acquire shares of Common Stock)derivative | -25,000 | - | - | 0 | Aug 20, 2025 |
| Aug 20, 2025 | Kara Cannon Chief Executive Officer | DDisposition to issuer Stock Option (to acquire shares of Common Stock)derivative | -55,400 | - | - | 0 | Aug 20, 2025 |
| Jan 16, 2025 | Jonathan Couchman director | AGrant or award Common Stock | +142,897 | $0.00 | $0 | 142,897 | Jan 17, 2025 |
| Jan 16, 2025 | Steven J Pully director | AGrant or award Common Stock | +142,897 | $0.00 | $0 | 239,992 | Jan 17, 2025 |
| Jan 16, 2025 | Bradley Louis Radoff director | AGrant or award Common Stock | +142,897 | $0.00 | $0 | 4,533,779 | Jan 17, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jonathan Couchmandirector
- Kara CannonChief Executive Officer
- Patricia EckertChief Financial Officer
- Steven J Pullydirector
- Bradley Louis Radoffdirector, owner
Questions about ENZ
Answered from the filings on this page, as of the latest one.
Are insiders buying ENZ?
No. In the last 90 days no insider at ENZO BIOCHEM INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ENZ on the open market?
No open-market trade has been scored at ENZO BIOCHEM INC. The latest Form 4 on file was filed on Aug 20, 2025 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at ENZO BIOCHEM INC?
5 people have filed a Form 4 at ENZO BIOCHEM INC, among them Jonathan Couchman (director), Kara Cannon (Chief Executive Officer), Patricia Eckert (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.